このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

認知症や糖尿病患者のケアを導くための共有意思決定の強化 (CGM ASSIST)

2026年10月2日 更新者:April Savoy、Indiana University

アルツハイマー病と糖尿病患者の個別化されたケアを促し導くための共有意思決定の強化

The goal of this study is to test CGM ASSIST. This is a digital tool that uses an interactive information display-an easy-to-read screen designed to help people with dementia (or memory loss) and diabetes, as well as their caregivers and doctors.

Managing diabetes is often difficult for people with memory issues. This study uses a Continuous Glucose Monitor (CGM), which is a device that tracks blood sugar levels in real-time. CGM ASSIST adds a new way to see this data through interactive displays. These displays show clear information and medical guidelines to help patients and caregivers make sense of the glucose readings.

The study aims to:

  • Increase Awareness: Help patients and caregivers recognize the dangers of low blood sugar (hypoglycemia) and how to treat it.
  • Improve Teamwork: Encourage "shared decision-making," where patients, caregivers, and doctors work together to make health choices.
  • Test Feasibility: See if it is easy and helpful for people with memory loss to use these interactive displays in their daily lives.
  • Understand Experiences: Learn how the thoughts and feelings of patients and families affect how they manage diabetes.

By using these interactive displays, the researchers hope to make it easier for families to understand their health needs and communicate better with their medical team.

Participants will:

  • Answer a survey about how they manage their diabetes
  • Learn how to use a Continuous Glucose Monitor and wear it for 14 days
  • Answer 3 brief telephone surveys during these 14 days
  • Complete a clinic visit with their doctor and answer a final survey on how this visit went using the CGM ASSIST report

調査の概要

状態

募集

条件

介入・治療

詳細な説明

Background and Clinical Significance Over 11 million Americans aged 65 and older live with diabetes mellitus (DM), and an estimated 13-20% of this population also has Alzheimer's disease and related dementias (ADRD). Hypoglycemia is a serious and frequent complication in this population, affecting 10-25% of patients and increasing the risk of coma, macrovascular events, and death.

A harmful cycle exists in ADRD-DM management: cognitive impairment hinders the detection of hypoglycemia and the management of glucose levels, while low glucose levels further impair cognition. Although clinical guidelines recommend de-intensifying medications and simplifying routines to reduce risk, these guidelines are often not implemented in clinical practice.

The Role of Continuous Glucose Monitoring (CGM) Continuous glucose monitoring (CGM) devices are effective tools for detecting hypoglycemia by tracking glucose levels every 5-15 minutes. While CGM has proven feasible in older adults without cognitive impairment, research indicates that standard CGM data reports are often difficult for patients and caregivers to interpret. This lack of interpretability creates a barrier to shared decision-making regarding behavior modifications, glycemic targets, and medication de-intensification.

Study Objective: CGM ASSIST This study aims to address these translational gaps by developing and testing CGM ASSIST. This intervention adapts standard CGM technology by adding interactive information displays (novel companion information guides) designed specifically for the ADRD-DM population and their caregivers.

The study follows a multi-phase approach:

Characterization of Needs: Identifying the unmet needs and decision-making processes of patient-caregiver dyads using CGM.

User-Centered Design: Engaging patients, caregivers, and clinicians in a design process to create the CGM ASSIST interactive reports.

Pilot Testing: Conducting a clinical trial to assess the feasibility, usability, and impact of the CGM ASSIST reports on shared decision-making and individualized care.

The long-term goal of this research is to improve the characterization of decision-making in adults with MCI and ADRD and to provide tools that help families identify and address unmet medical needs through better interpretation of clinical data.

研究の種類

介入

入学 (推定)

62

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:April Savoy, PhD
  • 電話番号:317-278-2194
  • メール:asavoy@iu.edu

研究連絡先のバックアップ

研究場所

    • Indiana
      • Indianapolis、Indiana、アメリカ、46202
        • 募集
        • Eskenazi Health
        • コンタクト:
          • Patricia Noblet

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

65年歳以上 (高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Patient-Caregiver Dyad Inclusion Criteria:

  • patient must have dual diagnosis of MCI or ADRD and diabetes (DM)
  • patient must have active prescriptions for DM
  • patient must have had at least one visit to an Eskenazi or IU Health primary care clinic within 12 months
  • patient must be able to provide assent and have a legally authorized representative (LAR) consent on their behalf if patient lacks capacity to consent
  • patient must have a caregiver aged 18 years or older who interacts daily, or almost daily, with the patient
  • patient and caregiver must both speak English
  • patient and caregiver must both reside in the community
  • dyad must have internet access

Patient-Caregiver Dyad Exclusion Criteria:

  • patient has terminal illness
  • use of an automated insulin delivery system
  • patient is receiving dialysis
  • patient is taking ascorbic acid during monitoring period
  • patient has existing implanted medical devices
  • patient has a bleeding disorder
  • patient has a pre-existing arm skin lesions
  • patient has an allergy to medical adhesive or isopropyl alcohol
  • patient has plans for imaging or diathermy treatment during the study period

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:ヘルスサービス研究
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Patient-Caregiver Dyads

Participants will wear a continuous glucose monitor

CGM education and glucose data collection for 14 days with a device. Interviews with dyads to assess experience and awareness of hypoglycemic events.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Feasibility- Recruitment
時間枠:8 months

Total number of participants enrolled divided by the total participants screened as eligible.

8 months
Feasibility- Retention
時間枠:2 months

Total number of participants who completed the study divided by the total number of participants enrolled in the study.

2 months
Feasibility- CGM Device Adherence
時間枠:14 days

This measures data completeness. Total number of days CGM worn and active divided by the total number of days in the observation period.

14 days
System Usability Scale
時間枠:2 months

The System Usability Scale (SUS) is a 10-item validated questionnaire used to evaluate the usability of the CGM ASSIST interactive information display. Participants rate each item on a 5-point Likert scale ranging from 1 (Strongly Disagree) to 5 (Strongly Agree). To calculate the final SUS score, the response for each odd-numbered item is reduced by 1, and the response for each even-numbered item is subtracted from 5. These adjusted scores are then summed and multiplied by 2.5. The total score ranges from 0 to 100. A higher score indicates better usability (e.g., a score above 68 is generally considered above average).

2 months
CollaboRATE Questionnaire
時間枠:2 months

The CollaboRATE questionnaire is a 3-item validated patient-reported measure used to assess the level of shared decision-making during clinical encounters. The three items focus on how much effort was made: 1) to help the participant understand their health issues, 2) to listen to what matters most to the participant, and 3) to include the participant's preferences in the choice of next steps. Each item is scored on a 5-point Likert scale ranging from 1 (No effort was made) to 5 (Every effort was made). For each participant, a total score is calculated by summing the scores of the three items. The total score ranges from 3 to 15. A higher score indicates a higher perceived level of shared decision-making.

2 months
Number of Changes in Diabetes Management
時間枠:12 months

This measure tracks the total number of management changes made to a participant's diabetes care plan based on medical record review. A "change" is defined as any of the following: 1) Initiation of new medications or technology, 2) New referrals to specialists or community services, 3) Discontinuation of existing medications, and 4) Modification (increase or decrease) of current medication dosages.

12 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Hypoglycemia - Time Below Range (TBR)
時間枠:14 days

The percentage of time the participant spent with glucose levels below the target range. Percentage = glucose readings and time 54-69 mg/dL / total amount of readings and time monitored [CGM performs calculation]. This includes Level 1 hypoglycemia (54-69 mg/dL) and Level 2 hypoglycemia (<54 mg/dL).

14 days
Glucose Level - Time In Range (TIR)
時間枠:14 days

Percentage of time the participant spent within the target glucose range of 70-180 mg/dL. Percentage = glucose readings and time 70-180 mg/dL / total amount of readings and time monitored [CGM performs calculation].

14 days
Glucose Management Indicator (GMI)
時間枠:14 days

Estimated HbA1c percentage based on the average glucose levels captured by the CGM. Automated calculation based on 14 days of CGM data [CGM performs calculation]

14 days
Glucose Variability (%GV)
時間枠:14 days

Oscillations in blood glucose levels: Measurement of fluctuations of glucose or other related parameters of glucose homoeostasis over a given interval of time (i.e., within a day, between days or longer term). Calculation as the coefficient of variation (%CV). The goal for stable glycemic control is a variability of ≤36% [CGM performs calculation]

14 days
Mean Glucose Level
時間枠:14 days

This mean is calculated by taking the total sum of glucose averages divided by the total number of days of glucose readings [CGM performs calculation].

14 days

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • 主任研究者:April Savoy, PhD、Indiana University

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年9月29日

一次修了 (推定)

2027年6月30日

研究の完了 (推定)

2027年6月30日

試験登録日

最初に提出

2022年11月11日

QC基準を満たした最初の提出物

2022年12月1日

最初の投稿 (実際)

2022年12月8日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月5日

QC基準を満たした最後の更新が送信されました

2026年10月2日

最終確認日

2026年8月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 13925
  • 1K01AG076971 (米国 NIH グラント/契約)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

はい

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。